

# Market Announcement

29 May 2023

---

## Zelira Therapeutics Limited (ASX: ZLD) – Trading Halt

### Description

The securities of Zelira Therapeutics Limited ('ZLD') will be placed in trading halt at the request of ZLD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 31 May 2023 or when the announcement is released to the market.

### Issued by

**Sam Dorland**

Adviser, Listings Compliance

29 May 2023

Australian Securities Exchange Limited  
40 Central Park  
152 – 158 St Georges Terrace  
PERTH WA 6000  
Attention: Sean Maloney  
By email only: Sean.Maloney@asx.com.au

Dear Sir,

### TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Zelira Therapeutics Limited ('the Company', ASX: **ZLD**) requests the granting of a trading halt in ZLD's ordinary securities listed on the Australian Securities Exchange (ASX).

The Company provides the following information in relation to the request:

1. The trading halt is requested pending an announcement by the Company in relation to top line results of its IRB-approved multi-arm head-to-head study of its proprietary diabetic nerve pain drug against a major Big Pharmaceutical company's multi-billion-dollar revenue drug (Trial);
2. The Company requests an immediate trading halt and anticipates that the trading halt remain in place until the earlier of the commencement of trading on Wednesday, 31 May 2023 or the making of an announcement in respect to the Trial; and
3. ZLD confirms that it is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely



Tim Slate  
**Company Secretary**

**For further information please contact:**

**Company**

Dr Oludare Odumosu  
Managing Director & CEO  
T: +1 909 855 0675  
E: [oodumosu@zeliratx.com](mailto:oodumosu@zeliratx.com)

**Investors**

Ronn Bechler  
Executive Director, Automic Group  
T: +61 400 009 774  
E: [ronn.bechler@automicgroup.com.au](mailto:ronn.bechler@automicgroup.com.au)

**About Zelira Therapeutics ([www.zeliratx.com](http://www.zeliratx.com))**

ACN 103 782 378

**Australia**

Level 3  
101 St Georges Terrace  
Perth WA 6000  
AUSTRALIA  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
E: [enquiries@zeliratx.com](mailto:enquiries@zeliratx.com)  
W: [www.zeliratx.com](http://www.zeliratx.com)

**USA**

5110 Campus Drive  
Suite 150  
Plymouth Meeting, PA  
19462  
UNITED STATES OF AMERICA  
Tel: +1 484-630-0650

**Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF)** Zelira is a leading global biopharmaceutical company in the research, development and commercialisation of clinically validated cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain as well as offering over the counter [OTC] products.

Zelira's Rx business generates revenue from two proprietary medications, HOPE® and ZENIVOL®. The Company has two proprietary formulations under the HOPE® brand that are generating revenue in Australia, Washington, D.C., Pennsylvania and Louisiana.

Zelira is also generating revenue in Australia from its proprietary and patented ZENIVOL® – the world's first clinically validated cannabinoid drug for treatment of chronic insomnia. Zelira will also be expanding commercialisation of ZENIVOL® into Germany via its German commercialisation partner Adjupharm GmbH following recent approval from German regulatory authority BfArM.

Zelira's OTC products in the oral and dermatology health care sectors are also generating revenue. Zelira, in partnership with SprinJeneCBD, launched a full line of oral care products, currently generating revenue in the US. The SprinJeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilising proprietary and patented technology. Zelira also launched in 2021 the RAF FIVE™ brand, which consists of five OTC acne treatment products using a proprietary formulation incorporating cannabidiol (CBD).

Zelira has developed Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology under the brand name Zyraydi, that solves the problem of non-uniformity and separation of cannabinoid from powder bed, opening new ways to develop pharmaceutical grade solid oral dosage forms such as capsules and tablets. Zelira will be assessing opportunities for commercialisation of this technology.

The Company conducts its work in partnership with world-leading researchers and organisations which since inception includes Curtin University in Perth, Australia; the Telethon Kids Institute in Perth, Australia; the University of Western Australia, in Perth, Australia; St Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

For further information, please visit: [zeliratx.com](http://zeliratx.com)